利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

45 条记录 (耗时 0.043 秒)

    METHODS OF USING A G PROTEIN-COUPLED RECEPTOR TO IDENTIFY PEPTIDE YY (PYY) SECRETAGOGUES AND COMPOUNDS USEFUL IN THE TREATMENT OF CONDITIONS MODULATED BY PYY
    31.
    发明申请
    METHODS OF USING A G PROTEIN-COUPLED RECEPTOR TO IDENTIFY PEPTIDE YY (PYY) SECRETAGOGUES AND COMPOUNDS USEFUL IN THE TREATMENT OF CONDITIONS MODULATED BY PYY 有权
    使用G蛋白偶联受体鉴定PYY（PYY）秘密肽和化合物的方法可用于治疗由PYY调节的病症

    公开(公告)号：US20090253153A1

    公开(公告)日：2009-10-08

    申请号：US12391097

    申请日：2009-02-23

    申请人： ZHI-LIANG CHU ,  James N. Leonard ,  Robert M. Jones

    发明人： ZHI-LIANG CHU ,  James N. Leonard ,  Robert M. Jones

    IPC分类号： G01N33/53

    CPC分类号： G01N33/68 ,  G01N33/5044 ,  G01N2333/726 ,  G01N2800/042 ,  G01N2800/044 ,  G01N2800/065 ,  G01N2800/108 ,  G01N2800/323

    摘要： The present invention relates to methods of using GPR119 receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY, such as conditions modulated by stimulation of NPY Y2 receptor (Y2R). Agonists of GPR119 receptor are useful as therapeutic agents for treating or preventing a condition modulated by PYY, such as a condition modulated by stimulation of Y2R. Conditions modulated by PYY such as may be a condition modulated by stimulation of Y2R include bone-related conditions, metabolic disorders, angiogenesis-related conditions, ischemia-related conditions, convulsive disorders, malabsorptive disorders, cancers, and inflammatory disorders.

    摘要翻译： 本发明涉及使用GPR119受体鉴定肽YY（PYY）促分泌素和可用于治疗由PYY调节的病症的化合物的方法，例如通过刺激NPY Y2受体（Y2R）调节的病症。 GPR119受体的激动剂可用作治疗或预防由PYY调节的病症的治疗剂，例如通过刺激Y2R调节的病症。 由PYY调节的病症例如可能是通过Y2R刺激调节的病症包括骨相关病症，代谢紊乱，血管生成相关病症，缺血相关病症，惊厥症，吸收不良障碍，癌症和炎症性疾病。

    Gpr41 and Modulators Thereof for the Treatment of Insulin-Related Disorders
    32.
    发明申请
    Gpr41 and Modulators Thereof for the Treatment of Insulin-Related Disorders 审中-公开
    Gpr41及其调节剂治疗胰岛素相关性疾病

    公开(公告)号：US20080312277A1

    公开(公告)日：2008-12-18

    申请号：US11666910

    申请日：2005-11-01

    申请人： James N. Leonard ,  Zhi Liang Chu ,  Marc A. Bruce ,  P. Douglas Boatman

    发明人： James N. Leonard ,  Zhi Liang Chu ,  Marc A. Bruce ,  P. Douglas Boatman

    IPC分类号： A61K31/47 ,  G01N33/566 ,  C07D215/38 ,  A61P3/10 ,  A61K31/4709 ,  C07D407/04

    CPC分类号： G01N33/66 ,  G01N2500/04

    摘要： The present invention relates to a method for identifying a glycemic stabilizing compound by: a) contacting a candidate compound with GPR41, and b) determining whether GPR41 functionality is modulated, where a modulation in GPR41 functionality is indicative of the candidate compound being a glycemic stabilizing compound. In addition, the invention relates to a method for identifying a glycemic stabilizing compound, comprising: a) contacting a candidate compound with GPR41, and b) determining whether GPR41 functionality is increased, wherein an increase in GPR41 functionality is indicative of the candidate compound being a glycemic stabilizing compound. Further, the invention relates to a method for identifying a glycemic stabilizing compound, comprising: a) contacting a candidate compound with GPR41, and b) determining whether GPR41 functionality is decreased, wherein a decrease in GPR41 functionality is indicative of the candidate compound being a glycemic stabilizing compound.

    摘要翻译： 本发明涉及通过以下方式鉴定血糖稳定化合物的方法：a）使候选化合物与GPR41接触，和b）确定是否调节GPR41功能性，其中GPR41官能度的调节指示候选化合物是血糖稳定剂 复合。 此外，本发明涉及一种鉴定血糖稳定化合物的方法，包括：a）使候选化合物与GPR41接触，和b）确定GPR41的功能是否增加，其中GPR41功能的增加指示候选化合物为 血糖稳定化合物。 此外，本发明涉及用于鉴定血糖稳定化合物的方法，其包括：a）使候选化合物与GPR41接触，和b）确定GPR41的功能性是否降低，其中GPR41官能度的降低指示候选化合物为 血糖稳定化合物。

    GPR35 and modulators thereof for the treatment of metabolic-related disorders
    33.
    发明申请
    GPR35 and modulators thereof for the treatment of metabolic-related disorders 有权
    GPR35及其调节剂用于治疗代谢相关疾病

    公开(公告)号：US20070077602A1

    公开(公告)日：2007-04-05

    申请号：US11638343

    申请日：2006-12-13

    申请人： James Leonard ,  Zhi Liang Chu

    发明人： James Leonard ,  Zhi Liang Chu

    IPC分类号： G01N33/567 ,  A61K31/66 ,  A61K31/426 ,  A61K31/401 ,  A61K31/366 ,  A61K31/22

    CPC分类号： G01N33/6893 ,  A61K31/425 ,  G01N2333/726 ,  G01N2500/00

    摘要： The present invention relates to a method for identifying a metabolic stabilizing compound, comprising: a) contacting a candidate compound with GPR35, and b) determining whether GPR35 functionality is increased, wherein an increase in GPR35 functionality is indicative of the candidate compound being a metabolic stabilizing compound. The invention further relates to a method for treating or preventing a metabolic-related disorder, comprising administering to an individual in need thereof an effective amount of a GPR35 modulator.

    摘要翻译： 本发明涉及用于鉴定代谢稳定化合物的方法，包括：a）使候选化合物与GPR35接触，和b）确定GPR35的功能是否增加，其中GPR35功能的增加指示候选化合物是代谢 稳定化合物。 本发明进一步涉及治疗或预防代谢相关疾病的方法，其包括向有需要的个体施用有效量的GPR35调节剂。

    5-Ht6 Receptor and Modulators Thereof for the Treatment of Insulin-Related Disorders
    37.
    发明申请
    5-Ht6 Receptor and Modulators Thereof for the Treatment of Insulin-Related Disorders 审中-公开
    5-Ht6受体及其调节剂用于治疗胰岛素相关性疾病

    公开(公告)号：US20110319451A1

    公开(公告)日：2011-12-29

    申请号：US13055128

    申请日：2009-07-22

    申请人： James N. Leonard ,  Zhi-Liang Chu ,  Brian M. Smith

    发明人： James N. Leonard ,  Zhi-Liang Chu ,  Brian M. Smith

    IPC分类号： A61K31/4439 ,  A61P3/10 ,  C12Q1/02 ,  A61P3/04 ,  A61P3/08 ,  A61P5/48 ,  A61P3/06

    CPC分类号： G01N33/942 ,  G01N2333/62 ,  G01N2500/04 ,  G01N2800/042

    摘要： The present invention relates to a method for identifying a glycemic stabilizing compound, by: a) contacting a candidate compound with a 5-HT6 receptor, b) determining whether 5-HT6 receptor functionality is increased, and c) determining whether a glycemic marker is directly modulated, where an increase in 5-HT6 receptor functionality and direct modulation of a glycemic marker identifies the candidate compound as the glycemic stabilizing compound. In addition, the invention relates to a method for identifying a glycemic stabilizing compound, by: a) contacting a single dose of a candidate compound with a 5-HT6 receptor, b) determining whether 5-HT6 receptor functionality is increased, and c) determining whether a glycemic marker is directly modulated, where an increase in 5-HT6 receptor functionality and direct modulation of a glycemic marker identifies the candidate compound as the glycemic stabilizing compound. Further, the invention relates to a method for identifying a glycemic stabilizing compound, by: a) contacting a candidate compound with a 5-HT6 receptor in an isolated cell, b) determining whether 5-HT6 receptor functionality is increased, and c) determining whether a glycemic marker is directly modulated, where an increase in 5-HT6 receptor functionality and direct modulation of a glycemic marker identifies the candidate compound as the glycemic stabilizing compound.

    摘要翻译： 本发明涉及通过以下方式来鉴定血糖稳定化合物的方法：a）使候选化合物与5-HT 6受体接触，b）确定5-HT 6受体功能是否增加，以及c）确定血糖标志物是否为 直接调节，其中5-HT 6受体功能的增加和血糖标志物的直接调节将候选化合物鉴定为血糖稳定化合物。 此外，本发明涉及通过以下方式鉴定血糖稳定化合物的方法：a）使单剂量的候选化合物与5-HT 6受体接触，b）确定5-HT 6受体功能是否增加，以及c） 确定血糖标志物是否被直接调节，其中5-HT 6受体功能的增加和血糖标志物的直接调节将候选化合物识别为血糖稳定化合物。 此外，本发明涉及通过以下方式鉴定血糖稳定化合物的方法：a）在分离的细胞中使候选化合物与5-HT 6受体接触，b）确定5-HT 6受体功能是否增加，以及c）确定 是否直接调节血糖标志物，其中5-HT 6受体功能的增加和血糖标志物的直接调节将候选化合物鉴定为血糖稳定化合物。

    Methods of using GPR119 to identify compounds useful for increasing bone mass in an individual
    38.
    发明授权
    Methods of using GPR119 to identify compounds useful for increasing bone mass in an individual 失效
    使用GPR119受体鉴定GIP促分泌素的方法

    公开(公告)号：US08026074B2

    公开(公告)日：2011-09-27

    申请号：US12700394

    申请日：2010-02-04

    申请人： Zhi-Liang Chu ,  James N. Leonard

    发明人： Zhi-Liang Chu ,  James N. Leonard

    IPC分类号： G01N33/53 ,  G01N33/567 ,  C12Q1/02

    CPC分类号： G01N33/74 ,  G01N33/5005 ,  G01N2333/726 ,  G01N2800/108

    摘要： The present invention relates to methods of using GPR119 receptor to identify compounds useful for increasing bone mass in an individual. Agonists of GPR119 receptor are useful as therapeutic agents for treating or preventing a condition characterized by low bone mass, such as osteoporosis, and for increasing bone mass in an individual. Agonists of GPR119 receptor promote bone formation in an individual.

    摘要翻译： 本发明涉及使用GPR119受体鉴定可用于增加个体骨量​​的化合物的方法。 GPR119受体的激动剂可用作治疗或预防以低骨量为特征的疾病如骨质疏松症和用于增加个体骨量​​的治疗剂。 GPR119受体的激动剂促进个体的骨形成。

    Methods of using GPR119 to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
    39.
    发明授权
    Methods of using GPR119 to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY 有权
    使用GPR119鉴定肽YY（PYY）促分泌素和可用于治疗由PYY调节的病症的化合物的方法

    公开(公告)号：US07838254B2

    公开(公告)日：2010-11-23

    申请号：US12391097

    申请日：2009-02-23

    申请人： Zhi-Liang Chu ,  James N Leonard ,  Robert M Jones

    发明人： Zhi-Liang Chu ,  James N Leonard ,  Robert M Jones

    IPC分类号： G01N33/53 ,  G01N33/567 ,  C12P21/06 ,  C12N1/20 ,  C12N15/74

    CPC分类号： G01N33/68 ,  G01N33/5044 ,  G01N2333/726 ,  G01N2800/042 ,  G01N2800/044 ,  G01N2800/065 ,  G01N2800/108 ,  G01N2800/323

    摘要： The present invention relates to methods of using GPR119 receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY, such as conditions modulated by stimulation of NPY Y2 receptor (Y2R). Agonists of GPR119 receptor are useful as therapeutic agents for treating or preventing a condition modulated by PYY, such as a condition modulated by stimulation of Y2R. Conditions modulated by PYY such as may be a condition modulated by stimulation of Y2R include bone-related conditions, metabolic disorders, angiogenesis-related conditions, ischemia-related conditions, convulsive disorders, malabsorptive disorders, cancers, and inflammatory disorders.

    摘要翻译： 本发明涉及使用GPR119受体鉴定肽YY（PYY）促分泌素和可用于治疗由PYY调节的病症的化合物的方法，例如通过刺激NPY Y2受体（Y2R）调节的病症。 GPR119受体的激动剂可用作治疗或预防由PYY调节的病症的治疗剂，例如通过刺激Y2R调节的病症。 由PYY调节的病症例如可能是通过Y2R刺激调节的病症包括骨相关病症，代谢紊乱，血管生成相关病症，缺血相关病症，惊厥症，吸收不良障碍，癌症和炎症性疾病。